Medpace (MEDP)
(Delayed Data from NSDQ)
$333.45 USD
-0.35 (-0.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $334.83 +1.38 (0.41%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$333.45 USD
-0.35 (-0.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $334.83 +1.38 (0.41%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum B VGM
Zacks News
QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu
by Zacks Equity Research
QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.
Top 5 Non-Tech Winners YTD With More Potential for Growth
by Nalak Das
Five Nasdaq listed non-tech stocks that have provided more than 40% returns year to date and have more potential for growth. These are: COIN, MEDP, WING, TXRH, TSCO.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).
Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to record strong procedure volume in 2024 in both the Knees and Hips businesses, banking on an improved market scenario.
Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
by Zacks Equity Research
Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.
Medpace (MEDP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medpace (MEDP) reachead $389.41 at the closing of the latest trading day, reflecting a +0.79% change compared to its last close.
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
by Zacks Equity Research
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
by Zacks Equity Research
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay
by Zacks Equity Research
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
by Zacks Equity Research
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
Charles River (CRL) Launches Viral Vector Tech Transfer Program
by Zacks Equity Research
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
QIAGEN (QGEN) Develops Test for Research and CDx Application
by Zacks Equity Research
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success
by Zacks Equity Research
Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.
SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon
by Zacks Equity Research
SenesTech (SNES) looks to leverage the convenience and reach of e-commerce to expand its market share.
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
by Zacks Equity Research
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
Reasons to Hold Charles River (CRL) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Here is Why Growth Investors Should Buy Medpace (MEDP) Now
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant
by Zacks Equity Research
Inspira Technologies' (IINN) ART100 recent approval highlights the company's innovative advancements in medical technology.
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
by Zacks Equity Research
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
Medpace (MEDP) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Medpace (MEDP) settling at $390.81, representing a +0.07% change from its previous close.
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
by Zacks Equity Research
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
Here's Why Investors Should Retain ICON (ICLR) Stock Now
by Zacks Equity Research
Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.
Stereotaxis (STXS) Gets CE Recertification for Approved Products
by Zacks Equity Research
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.